Anticoagulants: Heparin, Warfarin, NOACs & Reversal Agents

Anticoagulants: Heparin, Warfarin, NOACs & Reversal Agents

A practical guide for clinicians, nurses, and medical learners

What Is This?

Anticoagulants prevent blood clots by interfering with the coagulation cascade. Clinicians use them to treat or prevent thromboembolic events (e.g., deep vein thrombosis [DVT], pulmonary embolism [PE], stroke in atrial fibrillation [AFib], or mechanical heart valves). Reversal agents restore normal clotting when bleeding occurs or urgent surgery is needed.

Why use them today? - Heparin (fast-acting, IV/SC) is the drug of choice for acute clot management (e.g., MI, PE). - Warfarin (oral, long-term) is the standard for chronic anticoagulation (e.g., AFib, prosthetic valves). - NOACs (non-vitamin K oral anticoagulants) offer predictable dosing without routine monitoring (e.g., apixaban, rivaroxaban). - Reversal agents save lives in bleeding emergencies (e.g., trauma, intracranial hemorrhage).

Why It Matters

• Prevents strokes, PEs, and DVTs—major causes of disability and death.
• Balances risk: Too little anticoagulation-clots; too much-bleeding.
• NOACs are replacing warfarin in many settings due to fewer drug interactions and no need for INR monitoring.
• Reversal agents are critical in emergencies (e.g., a patient on warfarin with a GI bleed needs vitamin K + PCC now).

Core Concepts

1. The Coagulation Cascade

• Intrinsic pathway (measured by PTT): Activated by blood vessel injury (e.g., contact with collagen).
• Extrinsic pathway (measured by PT/INR): Triggered by tissue factor (e.g., trauma, surgery).
• Common pathway: Both converge to form fibrin clots.

2. Key Anticoagulants & Their Targets

3. Reversal Agents

4. When to Reverse?

• Major bleeding (e.g., intracranial, retroperitoneal, GI bleed with hemodynamic instability).
• Urgent surgery (e.g., emergency CABG, trauma).
• Over-anticoagulation (e.g., INR > 10 with no bleeding-hold warfarin + vitamin K).

How It Works

Heparin

1. Binds antithrombin III (ATIII)-accelerates its inhibition of thrombin (IIa) and factor Xa.
2. Monitor with PTT: Target is 1.5–2.5× baseline (e.g., if baseline PTT is 30 sec, target is 45–75 sec).
3. Short half-life: Effects wear off in 1–2 hours after stopping infusion.

Warfarin

1. Blocks vitamin K epoxide reductase-depletes factors II, VII, IX, X (and proteins C/S).
2. Monitor with INR: Goal is 2–3 for most indications (e.g., AFib, DVT); 2.5–3.5 for mechanical mitral valves.
3. Delayed onset: Takes 5–7 days to reach therapeutic INR (bridging with heparin/LMWH needed).

NOACs

1. Directly inhibit Xa (apixaban, rivaroxaban) or IIa (dabigatran).
2. No routine monitoring (but check renal function—dose adjustments needed in CKD).
3. Rapid onset/offset: Peak effect in 2–4 hours; cleared in 24–48 hours (except dabigatran in renal failure).

Reversal Agents

• Protamine: Positively charged molecule binds negatively charged heparin.
• Vitamin K: Replenishes vitamin K-dependent clotting factors (takes 6–24 hours).
• PCC: Contains factors II, VII, IX, X (works in minutes).
• Idarucizumab/Andexanet: Specific antidotes for dabigatran and Xa inhibitors.

Hands-On / Getting Started

Prerequisites

• Knowledge: Coagulation cascade, drug mechanisms, lab interpretation (PTT, INR).
• Tools: IV access, POC INR/PTT machines (if available), reversal agents on formulary.

Step-by-Step: Managing a Warfarin Bleed

Scenario: Patient on warfarin (INR 4.2) presents with melena + hypotension.

1. Assess severity:
2. Major bleed? (e.g., BP < 90, Hb drop > 2 g/dL)-reverse immediately.

3. Minor bleed? (e.g., epistaxis)-hold warfarin, monitor.

4. Stop warfarin and give vitamin K: plaintext Vitamin K 10 mg IV (slow infusion over 30 min to avoid anaphylaxis).

5. Administer PCC (if available): plaintext 4-factor PCC 50 units/kg IV (max 5000 units).
6. Recheck INR in 30 min:
7. If INR > 1.5, consider additional PCC.
8. Monitor for re-bleeding:
9. Repeat Hb, BP, and INR q4–6h.

Expected Outcome

• INR < 1.5 within 30 min (PCC) or 6–24 hours (vitamin K).
• Bleeding stops; patient stabilizes.

Common Pitfalls & Mistakes

1. Overcorrecting INR in Warfarin Patients

• Mistake: Giving too much vitamin K (e.g., 10 mg IV) to a patient with INR 3.5 and no bleeding.
• Why it’s bad: Causes warfarin resistance for weeks.
• Fix: For INR 4.5–10 with no bleeding, hold warfarin + oral vitamin K 1–2.5 mg.

2. Ignoring Renal Function with NOACs

• Mistake: Prescribing dabigatran 150 mg BID to a patient with CrCl 20 mL/min.
• Why it’s bad: Dabigatran is 80% renally cleared-accumulation-bleeding.
• Fix: Use apixaban 2.5 mg BID (dose-adjusted for renal impairment).

3. Using Protamine for LMWH Overdose

• Mistake: Giving protamine 1 mg per 1 mg enoxaparin for a massive LMWH overdose.
• Why it’s bad: Protamine only neutralizes ~60% of LMWH’s anti-Xa activity.
• Fix: For life-threatening LMWH bleeds, consider PCC or recombinant factor VIIa (off-label).

4. Forgetting to Bridge Warfarin

• Mistake: Starting warfarin without heparin/LMWH in a patient with acute DVT/PE.
• Why it’s bad: Warfarin’s initial effect is prothrombotic (depletes protein C/S first).
• Fix: Bridge with heparin/LMWH for 5 days until INR is therapeutic.

5. Misinterpreting PTT in Heparin Therapy

• Mistake: Assuming PTT > 100 sec is always due to heparin.
• Why it’s bad: Lupus anticoagulant, factor deficiencies, or DIC can also prolong PTT.
• Fix: Check anti-Xa level if PTT is unexpectedly high/low.

Best Practices

For Heparin

• Start with a bolus (e.g., 80 units/kg) for acute clots (e.g., PE, MI).
• Adjust infusion rate based on PTT q6h until stable, then daily.
• Use nomograms (e.g., weight-based heparin protocol) to avoid under/overdosing.

For Warfarin

• Start low (e.g., 5 mg daily) in elderly, malnourished, or liver disease patients.
• Check INR every 2–3 days initially, then weekly-monthly once stable.
• Educate patients on dietary vitamin K consistency (e.g., avoid large fluctuations in leafy greens).

For NOACs

• Avoid in mechanical heart valves (warfarin is superior).
• Check renal function at baseline and every 6–12 months.
• Hold for procedures:
• Low bleed risk: Hold 24 hrs before.
• High bleed risk: Hold 48 hrs before (longer if CrCl < 50).

For Reversal

• Major bleed on warfarin?-PCC + vitamin K (not FFP—takes too long).
• NOAC bleed?-Andexanet alfa (if available) or PCC (off-label).
• Heparin bleed?-Protamine (1 mg per 100 units heparin).

Tools & Frameworks

Real-World Use Cases

1. Post-Op DVT Prophylaxis

• Scenario: Patient post-hip replacement.
• Anticoagulant: Enoxaparin 40 mg SC daily (or apixaban 2.5 mg BID).
• Monitoring: None (unless renal failure-anti-Xa).
• Reversal: Protamine (partial) for bleeding.

2. Atrial Fibrillation Stroke Prevention

• Scenario: 70-year-old with AFib (CHA?DS?-VASc = 3).
• Anticoagulant: Apixaban 5 mg BID (or warfarin if mechanical valve).
• Monitoring: None (NOAC) or INR q4 weeks (warfarin).
• Reversal: Andexanet alfa (apixaban) or PCC (warfarin).

3. Acute PE in the ED

• Scenario: 50-year-old with hypotension + PE.
• Anticoagulant: Heparin bolus (80 units/kg) + infusion (18 units/kg/hr).
• Monitoring: PTT q6h (target 60–80 sec).
• Reversal: Protamine if bleeding.

Check Your Understanding (MCQs)

Question 1

A 65-year-old man on warfarin (INR 3.2) is scheduled for colonoscopy tomorrow. What is the best management? A) Hold warfarin for 5 days, bridge with LMWH. B) Hold warfarin for 2 days, no bridging. C) Continue warfarin, give vitamin K 1 mg PO. D) Hold warfarin, give PCC 25 units/kg.

Correct Answer: B Explanation: For low-bleed-risk procedures (e.g., colonoscopy), hold warfarin 2–3 days before (INR will drop to ~1.5). Bridging is not needed unless high thrombotic risk (e.g., mechanical mitral valve). Why the distractors are tempting: - A: Overkill—bridging is only for high thrombotic risk (e.g., recent DVT/PE). - C: Vitamin K is not needed unless INR is supratherapeutic. - D: PCC is for emergency reversal, not elective procedures.

Question 2

A patient on dabigatran presents with intracranial hemorrhage. What is the first-line reversal agent? A) Vitamin K 10 mg IV B) Prothrombin complex concentrate (PCC) C) Idarucizumab (Praxbind) 5 g IV D) Fresh frozen plasma (FFP)

Correct Answer: C Explanation: Idarucizumab is the specific antidote for dabigatran. It binds dabigatran with high affinity and reverses anticoagulation within minutes. Why the distractors are tempting: - A: Vitamin K works for warfarin, not dabigatran. - B: PCC is off-label for dabigatran (less effective than idarucizumab). - D: FFP is ineffective for dabigatran reversal.

Question 3

A nurse calls because a patient on heparin infusion